CD93 and neoplasm: Zhang et al. confirmed lenalidomide’s ability to reverse PI3K-AKT pathway dysregulation and CD93 overexpression, while promoting the infiltration of CD8+ T cells, CD4+ T cells, and dendritic cells into the tumor.